ID1 and hepatocellular carcinoma: SMAD1 is best characterized for activating ID1 [26, 27], which promotes proliferation and confers drug resistance in hepatocellular carcinoma [28], colon cancer [29], lung cancer [30], and acute myeloid leukemia [31].